In the News

Evolving Icagen - Our Business Case Study

Our agency partner, That's Nice, LLC recently completed a case study on the evolving Icagen brand.

Future Trends in Ion Channel and Solute Transporter Drug Discovery

Intro:

Gene family members of the ion channel and solute transporter (SLC) families represent both historical targets of pharmaceutical significance and serve as exciting opportunities for current and future therapeutic development. The common property of ion movement for many of the SLCs lends itself to considering platforms used in ion channel research to enable early drug discovery. In addition, the convergence of advances in both genetic analysis and assay technology bodes well for the identification of the next generation of ion channel and transporter-based drugs in the near future.

Icagen 'Home Again' at Durham HQ

Icagen relocates its headquarter office back to North Carolina. Located in the Durham/ RTP area off of Emperor Boulevard.

XRpro's Revamped Icagen, Inc. May See Hiring, CEO Tells BioSpace

BioSpace

XRpro Resurrects Icagen with Buy of Some Pfizer Ion Channel Assets

Xconomy

Icagen, acquired by Pfizer in 2011, turns next chapter

Triangle Business Journal

Four years after buyout, Pfizer spins Icagen ion channel platform back out

FierceBiotech

XRpro Re-Launching Icagen After Acquiring Ion Channel Assets from Pfizer

Genetic Engineering News